Cheng et al [17] collected data from 121 newly diagnosed NPC patients before treatment and 332 healthy subjects and found that the sensitivity and specificity of single VCA-IgA were 93% and 87%, respectively. This evidence concerns the gene CD79A and nasopharyngeal carcinoma.